文献速递炎症性肠病消化内镜

肠道超声预测乌帕替尼治疗活动性克罗恩病原发性无应答与维持期复发

Intestinal Ultrasound Predicts Primary Non-Response and Maintenance Relapse in Upadacitinib-Treated Active Crohn's Disease: A Multicenter, Prospective Cohort Study.
PubMed 文献 · Aliment Pharmacol Ther · 2026-09-01

这项多中心前瞻性队列研究纳入122例接受乌帕替尼治疗的活动性克罗恩病患者并随访至52周,评估肠道超声对原发性无应答和维持期复发的预测价值。基线IBUS-SAS>60.20预测原发性无应答的OR为16.63,联合临床和内镜参数后AUC提升至0.865;诱导后未达到超声应答或缓解者维持期复发风险升高。

要点

  • 基线IBUS-SAS>60.20是乌帕替尼原发性无应答的强预测因子,OR 16.63。
  • 联合IBUS-SAS可显著提升原发性无应答预测效能,AUC 0.865 vs 0.670。
  • 诱导后未达超声应答或缓解者,15mg维持期复发风险显著升高。

核心结论

  • 早期肠道超声监测在临床和内镜参数之外,对预测乌帕替尼原发性无应答具有增量价值。
  • 诱导后未达到超声应答或缓解,可能识别出15mg维持期复发风险升高的患者。

研究设计与样本

  • 多中心前瞻性队列研究,纳入122例接受乌帕替尼治疗的活动性克罗恩病患者,随访至第52周。
  • 纵向收集人口学、临床、生化、内镜和肠道超声数据,采用单因素logistic回归、ROC分析和似然比检验识别原发性无应答的最佳预测指标。
  • 采用生存分析评估诱导后超声目标与15mg维持期复发风险之间的关联。

主要发现

  • 基线肠道超声参数中,IBUS-SAS>60.20预测乌帕替尼原发性无应答的OR最高,为16.63(95%CI 6.54-42.29,p<0.001)。
  • 与临床和内镜参数相比,纳入IBUS-SAS显著改善原发性无应答预测(AUC 0.865 vs 0.670,LRT p<0.001,95%CI 0.802-0.929,敏感性82.98%,特异性77.33%,PPV 69.64%,NPV 87.88%)。
  • 第4周早期较差的肠道超声表现与原发性无应答显著相关,IBUS-SAS>47.80的OR最高,为26.25(95%CI 2.46-280.20,p=0.007)。
  • 在临床和内镜应答者中,未达到肠道超声应答或缓解与15mg维持期复发风险升高相关(Log-rank p=0.005,p<0.001)。

关键数值与推荐

  • 基线IBUS-SAS>60.20预测原发性无应答:OR 16.63(95%CI 6.54-42.29,p<0.001)。
  • 第4周IBUS-SAS>47.80预测原发性无应答:OR 26.25(95%CI 2.46-280.20,p=0.007)。
  • 联合IBUS-SAS预测原发性无应答:AUC 0.865(95%CI 0.802-0.929),敏感性82.98%,特异性77.33%,PPV 69.64%,NPV 87.88%。
  • 未达到肠道超声应答或缓解与维持期复发相关:Log-rank p=0.005,p<0.001。

临床怎么用

  • 对接受乌帕替尼治疗的活动性克罗恩病患者,可在基线及第4周采用IBUS-SAS进行肠道超声监测。
  • 基线IBUS-SAS>60.20或第4周IBUS-SAS>47.80提示原发性无应答风险较高,可辅助早期治疗决策。
  • 临床和内镜应答但未达到超声应答或缓解者,维持期需警惕复发风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intestinal ultrasound (IUS) is increasingly used to monitor activity and predict treatment outcomes in Crohn's disease (CD), but its role in predicting primary non-response (PNR) to Upadacitinib (UPA) and identifying maintenance relapse remains unclear. METHODS: In this multicenter prospective cohort study, 122 patients with active CD treated with UPA were followed through week 52. Demographic, clinical, biochemical, endoscopic and IUS data were collected longitudinally. Univariable logistic regression, ROC analysis and likelihood ratio test (LRT) identified the best PNR predictors. Survival analysis evaluated the association between post-induction ultrasound targets and the risk of relapse during 15-mg maintenance. RESULTS: Among baseline IUS parameters, IBUS-SAS > 60.20 demonstrated the highest odds ratio for predicting UPA PNR (OR 16.63, 95% CI 6.54-42.29, p < 0.001). Compared with clinical and endoscopic parameters, the inclusion of IBUS-SAS significantly improved PNR prediction (AUC 0.865 vs. 0.670, LRT p < 0.001, 95% CI 0.802-0.929, Sensitivity 82.98%, Specificity 77.33%, PPV 69.64% and NPV 87.88%). Early at week 4, worse IUS findings were significantly correlated with PNR, with IBUS-SAS > 47.80 showing the highest odds ratio (OR 26.25, 95% CI 2.46-280.20, p = 0.007). Among clinical and endoscopic responders, failure to achieve IUS response/remission was associated with an increased risk of relapse during 15-mg maintenance. (Log-rank p = 0.005, p < 0.001). CONCLUSION: Early IUS monitoring provides incremental value for predicting UPA PNR beyond clinical and endoscopic parameters. Failure to achieve IUS response/remission may identify patients at increased risk of relapse during 15-mg maintenance.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. He R, Huang Y, Han J, et al. Intestinal Ultrasound Predicts Primary Non-Response and Maintenance Relapse in Upadacitinib-Treated Active Crohn's Disease: A Multicenter, Prospective Cohort Study. Aliment Pharmacol Ther. 2026. PMID: 42681545. doi:10.1111/apt.70948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。